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The maternal embryonic leucine zipper kinase (MELK) has been
implicated in the regulation of cancer cell proliferation. RNAi-me-
diated MELK depletion impairs growth and causes G2/M
arrest in numerous cancers, but the mechanisms underlying
these effects are poorly understood. Furthermore, the MELK
inhibitor OTSSP167 has recently been shown to have poor
selectivity for MELK, complicating the use of this inhibitor as a
tool compound to investigate MELK function. Here, using a cell-
based proteomics technique called multiplexed kinase inhibitor
beads/mass spectrometry (MIB/MS), we profiled the selectivity
of two additional MELK inhibitors, NVS-MELK8a (8a) and
HTH-01-091. Our results revealed that 8a is a highly selective
MELK inhibitor, which we further used for functional studies.
Resazurin and crystal violet assays indicated that 8a decreases
triple-negative breast cancer cell viability, and immunoblotting
revealed that impaired growth is due to perturbation of cell cycle
progression rather than induction of apoptosis. Using double-
thymidine synchronization and immunoblotting, we observed
that MELK inhibition delays mitotic entry, which was associated
with delayed activation of Aurora A, Aurora B, and cyclin-de-
pendent kinase 1 (CDK1). Following this delay, cells entered and
completed mitosis. Using live-cell microscopy of cells harboring
fluorescent proliferating cell nuclear antigen, we confirmed that
8a significantly and dose-dependently lengthens G2 phase. Col-
lectively, our results provide a rationale for using 8a as a tool
compound for functional studies of MELK and indicate that
MELK inhibition delays mitotic entry, likely via transient G2/M
checkpoint activation.
The maternal embryonic leucine zipper kinase (MELK),2 also
known as MPK38 or pEg3, is a highly conserved member of the
AMPK family of kinases (1, 2). The proposed role of MELK in
regulation of cell growth has been controversial. MELK expres-
sion is increased in cancer relative to normal tissue (3), and high
levels of MELK are correlated with tumor grade, poor progno-
sis, radioresistance, and recurrence in multiple cancers (4 –10).
RNAi-mediated depletion of MELK has been shown to cause
impaired proliferation in a variety of cancers, including basal-
like breast (4), glioma (5), acute myeloid leukemia (11), high-
risk neuroblastoma (10), and hepatocellular carcinoma (9). In
triple-negative breast cancer (TNBC), knockdown of MELK
caused shrinking and radiosensitization of xenografts (4, 7).
Significantly, numerous studies have shown that RNAi effects
on growth are due specifically to MELK depletion by demon-
strating rescue with ectopic MELK expression (4, 5, 8, 9, 12, 13).
Complicating the interpretation of these findings, the require-
ment of MELK for cancer cell proliferation has been challenged
by studies showing that genomic deletion of MELK with
CRISPR/Cas9 caused no growth effects (14 –16). Other studies
contend that genomic MELK deletion does cause impaired pro-
liferation of cancer cells (17), although this effect may only
manifest under certain growth conditions (18).
The discordant results between acute MELK knockdown and
longer-term genetic inactivation is reminiscent of other key cell
cycle proteins whose essential roles are evident in experiments
following acute inactivation by RNAi or with small molecules,
but less clear in knockout experiments. Two examples in par-
ticular illustrate this phenomenon. First, the cyclin D-CDK4/6
complex is nonessential for proliferation in knockout cell lines
and virtually all mouse tissue (19, 20), but chemical inhibitors
halt progression into S phase in cell lines with a functional ret-
inoblastoma protein (21). This example is particularly relevant,
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given the growing clinical use of CDK4/6 inhibitors for the
treatment of cancer (22). Second, recent results using CRISPR/
Cas9 gene editing suggest that Bub1 is nonessential for mitotic
spindle checkpoint function in humans (23, 24), but it was later
shown that these “knockout” cells express low levels of a trun-
cated Bub1 protein, accounting for the negative results and lack
of a phenotype (25–27). Together, these results highlight the
importance of examining protein function using multiple,
orthogonal approaches and of using caution in interpreting
negative results from gene knockout experiments.
The recent controversy concerning the requirement of
MELK in cancer has underscored the need for a more compre-
hensive understanding of MELK function. MELK has been
reported to function in a multitude of processes, including cell
cycle progression (3, 4, 28), maintenance of cancer cell stem-
ness (5, 29, 30), protein synthesis (31), and apoptosis (8, 32–34).
Many of the functional studies of MELK have focused on the
role of this kinase in the cell cycle. MELK mRNA is cell cycle–
regulated, and accordingly, protein levels of MELK oscillate
throughout the cell cycle, with expression reaching a maximum
in G2/mitosis (M) phase, before declining upon mitotic exit (4,
35, 36). Depletion of MELK has been shown to cause a G2/M
arrest in cells (3, 4, 17, 37). Some studies have attributed this
effect to a role for MELK in the G2/M DNA damage checkpoint,
potentially mediated through interaction with CDC25B, a
phosphatase that regulates CDK1 activity at the G2/M check-
point (38). Additionally, loss of MELK activity may cause acti-
vation of the ATM/Chk2 DNA damage response (39). Other
studies indicate that MELK knockdown specifically impairs
mitotic progression. A circular relationship between MELK
and FoxM1 has been described, whereby MELK expression is
both regulated by this mitotic transcription factor, and phos-
phorylation by MELK regulates the activity and expression of
FoxM1 (28, 39). MELK may also regulate synthesis of the anti-
apoptotic protein MCL1 in M via interaction with eIF4B (31).
Overall, whereas a number of studies have uncovered putative
functions of MELK at G2/M, a comprehensive understanding of
the role of MELK at these phases of the cell cycle remains
elusive.
One of the key challenges in studying the biological func-
tions of MELK has been the lack of a selective inhibitor. The
most commonly used MELK inhibitor, OTSSP167 (OTS),
also referred to as OTS167, has shown potent antiprolifera-
tive and apoptotic effects against multiple cancer types,
including TNBC, acute myeloid leukemia, and high-risk
neuroblastoma (4, 10, 11, 40, 41). Consequently, OTS is cur-
rently in multiple phase I clinical trials for the treatment of
patients with advanced TNBC and refractory or relapsed
leukemia (NCT01910545, NCT02795520, NCT02768519,
and NCT02926690). While an effective inhibitor of cancer cell
viability, OTS is poorly selective for MELK. Recent publications
have shown that OTS is a broad-spectrum inhibitor that inhib-
its numerous kinases that are vital for proliferation, including
multiple mitotic kinases (42, 43). A number of studies have
relied upon OTS as a means to investigate the biological func-
tion of MELK; however, these results must be interpreted with
caution due to the poor selectivity of this inhibitor. More
recently, additional MELK inhibitors have been developed,
including MELK-T1 (39), NVS-MELK8a (8a) (44), HTH-01-
091 (HTH) (15), IN17 (45), and others (8, 46). 8a and HTH in
particular appear to have more favorable selectivity profiles
than OTS based upon kinase activity profiling assays (15, 44).
The key objectives of this study were to evaluate the selectiv-
ity profiles of three MELK inhibitors, 8a, HTH, and OTS, using
a cell-based assay, to identify a highly selective inhibitor to sub-
sequently investigate MELK function. To this end, we utilized a
chemical proteomics approach called multiplexed kinase inhib-
itor beads/mass spectrometry (MIB/MS) to characterize the
selectivity of these MELK inhibitors in TNBC cells (47, 48).
OTS was observed to be highly nonselective, in agreement with
previous studies, and HTH did not effectively inhibit MELK in
cells. In contrast, we found the inhibitor 8a to be highly selective
for MELK, providing the first reliable alternative to OTS for
functional MELK studies. Using 8a as a tool compound to probe
the function of MELK, we observed that MELK inhibition per-
turbed cell cycle progression by delaying entry into M, without
an induction of apoptosis. Collectively, our results provide a
rationale to utilize 8a for functional MELK studies as an orthog-
onal approach to knockdown and knockout techniques and
provide insight into the role of MELK in cell cycle progression,
specifically at the G2/M checkpoint.
Results
Identification of a selective MELK inhibitor by MIB/MS kinome
profiling
MIB/MS is a proteomics technology used for enriching
kinases from complex samples (47, 49). This technique can be
used for selectivity profiling of inhibitors in a cell-based fashion,
an application termed competition MIB/MS (see Fig. 1 for a
detailed description of the technology) (48). Selectivity can also
be assessed using MIB/MS by adding inhibitors directly to
lysates. A similar chemical proteomics approach, using kino-
beads and MS, was recently employed by Klaeger et al. (42) to
comprehensively define the selectivity of all clinical and Food
and Drug Administration–approved kinase inhibitors, validat-
ing the use of this approach for measuring inhibitor selectivity
in cells. We used the competition MIB/MS approach to profile
the selectivity of 8a and HTH in an effort to identify a highly
selective MELK inhibitor suitable for functional studies.
We first determined the kinase target landscape of OTS,
HTH, and 8a at a single concentration. MDA-MB-468 cells were
selected for initial experiments, as many previous studies uti-
lized this and other TNBC cell lines. MDA-MB-468 cells were
treated with a 1 M concentration of each putative MELK
inhibitor or DMSO for 30 min. Lysates from DMSO- or inhib-
itor-treated cells were flowed over columns packed with MIBs.
Kinases bound to MIBs in the absence or presence of inhibitors
were eluted and quantified by MS using label-free quantifica-
tion in MaxQuant with integrated Andromeda search engine.
The specificity of each inhibitor was analyzed for a total of 235
protein kinases quantified in this assay (Fig. S1). Examining the
20 protein kinases detected in lowest abundance after OTS,
HTH, or 8a treatment of cells (i.e. most prevented from binding
to MIBs), relative to DMSO treatment, revealed stark differ-
ences in the selectivity and potency of these three compounds
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(Fig. 2A). As reported previously, OTS exhibited broad speci-
ficity, with 52 protein kinases including MELK captured by
MIBs with at least 4-fold decreased abundance relative to
DMSO (OTS/DMSO 0.25). Moreover, OTS decreased the
binding of a number of kinases to MIBs more effectively than
MELK. This finding is in agreement with previous studies, con-
firming that OTS has very poor selectivity, despite high potency
for MELK (42, 43). HTH was found to have a much narrower
selectivity profile, with only five protein kinases captured with
at least 4-fold decreased abundance relative to DMSO, but sur-
prisingly MELK binding was largely unaffected by this com-
pound. These results suggest that HTH did not effectively
inhibit MELK in this cell-based assay, inconsistent with in vitro
enzyme assay data (15). By contrast, the target landscape of 8a
was observed to be extremely narrow, with MELK being the
only protein kinase captured with at least 4-fold decreased
abundance relative to DMSO. These results indicated that 8a is
the most selective of the three MELK inhibitors profiled using
Figure 1. Schematic of competition MIB/MS workflow and sample selectivity output data. MDA-MB-468 cells were treated with DMSO (negative control)
or MELK inhibitor for 30 min. This time point allows sufficient time for inhibitors to penetrate cells and engage kinase targets, but not for significant expression-
level changes. After harvest, cell lysates were flowed over columns containing kinase inhibitors immobilized on Sepharose beads, which bind kinases in the
cell lysates (top). Kinases bound to the added MELK inhibitor are unable to bind to the MIBs and thus are not captured. Following wash steps to remove
nonspecific binders, kinases were subsequently eluted and quantified by MS using label-free quantification. Kinases detected in lower abundance in MELK
inhibitor conditions relative to DMSO control (bottom) are prevented from binding to beads due to the inhibitor and thus are targets of that inhibitor.
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MIB/MS. Additional MS data, including number of peptides
identified, sequence coverage, and abundance ratios can be
found in Table S1, for this and all MS experiments.
Due to the striking specificity and potency differences
between 8a and HTH, we sought to further validate these
results in biological triplicate, again at a single concentration of
1 M. Subsequent competition MIB/MS results are displayed as
volcano plots to assess both kinase -fold change magnitude and
significance (Fig. 2B). With 8a treatment, MELK was the only
kinase that displayed statistically significant decreased binding
to MIBs, confirming the high selectivity of this compound. As
observed previously (Fig. 2A), HTH treatment did not signifi-
cantly decrease MELK capture, whereas binding of GAK,
CSNK2A2, CSNK2B, CSNK2A1, PIP4K2C, and RIPK2 were
significantly decreased. These results further confirm that 8a is
a highly selective MELK inhibitor in cells and underscore the
importance of determining compound selectivity in a cellular
context prior to biological studies.
Competition MIB/MS was next used to profile the selectivity
of 8a at 10, 100, and 1000 nM. As expected, we observed a dose-
dependent decrease in MELK binding to MIBs, with no major
off-target inhibition over this concentration range (Fig. S2).
Whereas high selectivity was maintained at 1 M 8a, we did not
observe greater than 90% loss of MELK binding to MIBs, sug-
gesting incomplete inhibition. Because the percentage inhibi-
tion of MELK required to elicit a phenotype is not well-defined,
we tested higher concentrations of 8a (3 and 10 M), with the
goal of assessing selectivity at concentrations required for
nearly total inhibition of binding to MIBs. Following MIB/MS,
221 protein kinases were quantified by label-free quantification
as above (Fig. S3), and the data were filtered to remove any
protein kinases that did not exhibit reduced binding at all three
concentrations in a dose-dependent manner. The 32 protein
kinases that met these criteria are displayed in a heat map (Fig.
2C). At 1 M, 8a was again observed to be highly selective for
MELK, with only MELK, STK11, and MAP2K4 captured with
4-fold less abundance, relative to DMSO. Notably, competition
MIB/MS results indicated that MELK was not detected at
quantifiable levels following 3 M 8a treatment, suggesting total
loss of MELK binding to MIBs, while maintaining a high level of
selectivity at this concentration. At 10 M, however, the speci-
ficity of 8a was decreased, with robust off-target kinase inhibi-
tion observed.
Whereas STK11 and MAP2K4 appear to exhibit decreased
binding in a somewhat dose-dependent manner, it should be
noted that neither exhibited significantly reduced binding with
1 M 8a treatment in biological triplicate (Fig. 2B). We further
tested the binding affinity of 8a for these kinases using the Euro-
finsDiscoverXKINOMEscanTMassay,whichquantitativelymea-
sures the ability of an inhibitor to compete with a kinase ligand.
8a was found to have no detectable binding affinity for STK11
(Kd  30 M) or MAP2K4 (Kd  17 M) at 3 M or lower,
whereas high affinity for MELK was observed (Kd  14 nM) (Fig.
S4). Taken together, results from this cell-based selectivity-pro-
filing assay indicate that treatment of cells with 8a at 1–3 M
concentrations is sufficient for moderately strong levels of inhi-
bition to nearly total inhibition of MELK, respectively, while
maintaining high selectivity for this kinase.
Effects of MELK inhibition on TNBC cell viability
MELK has been reported to play a role in TNBC proliferation
and radioresistance (4, 6, 7). In TNBC and other cancers, RNAi-
mediated depletion of this kinase impairs growth, an effect that
can be reversed with exogenous MELK rescue, indicating that
MELK may be an attractive therapeutic target (4, 5, 7, 8, 12, 13).
Recent results demonstrating that genetic knockout of MELK
may cause no growth phenotype have called into question the
approach of inhibiting this kinase as a cancer monotherapy (14,
15). In light of these disparate results, we sought to test whether
selective MELK inhibition with 8a impaired the proliferation of
two TNBC cell lines. Treatment of MDA-MB-231 and MDA-
MB-468 cells with 8a for 72 h caused decreased cell viability, as
measured by a resazurin assay, with an IC50 of 1.7 M  0.4 and
2.3 M  0.4, respectively (Fig. 3A). We further measured the
viability effects of 8a using long-term crystal violet cell-staining
assays. MDA-MB-231 and MDA-MB-468 cells were treated
with 8a for 8 or 14 days, respectively, prior to staining with
crystal violet. Similar IC50 values of between 1 and 3 M were
obtained for both cell lines (Fig. 3B), in agreement with shorter-
term resazurin assay results. Notably, this inhibition of cell via-
bility was observed at the same concentrations found to result
in selective, moderately strong to nearly total inhibition of
MELK (Fig. 2C).
We next examined whether reduced cell viability was medi-
ated through the induction of apoptosis or perturbation of cell
cycle progression. MDA-MB-468 cells were treated with 0.5, 1,
or 3 M 8a or with DMSO vehicle control, and cells were col-
lected over a 24-h time course. Samples were immunoblotted
for PARP/cleaved PARP; cyclins E1, A2, and B1; and phospho-
histone H3 (p-H3) (Ser-10), to measure effects on apoptosis and
cell cycle distribution (Fig. 3C). PARP cleavage was not
observed at any concentration or time point, indicating that 8a
did not induce apoptosis. 8a treatment also had no effect on the
abundance of the measured cyclins, but there was a dose-de-
Figure 2. 8a is a highly selective MELK inhibitor. A, MDA-MB-468 cells were treated for 30 min with either DMSO or 1 M 8a, HTH, or OTS. Cells were harvested,
and competition MIB/MS was completed, as described under “Experimental procedures,” to determine the selectivity profile of each MELK inhibitor. The 20
kinases detected in lowest abundance, relative to DMSO control, are displayed for each inhibitor. Arrows indicate the bar corresponding to MELK in each
selectivity profile. Results shown are from one experiment. B, MDA-MB-468 cells were treated for 30 min with either DMSO, 1 M 8a, or 1 M HTH in three
biological replicates (distinct from the replicate shown in A). Competition MIB/MS was used to determine selectivity as in A, and results are displayed as volcano
plots to show both the -fold change and significance of the quantified changes in kinase abundance. Kinases with high significance and log2 -fold change 1
are colored red and labeled. Kinases with only log2 -fold change 1 are colored yellow. Kinases with log2 -fold change 1 and nonsignificance are colored
gray. t statistics were calculated by empirical Bayes moderation of S.E. values toward the S.E. estimated from all kinases (67). The Benjamini–Hochberg method
was used for multiple-test correction with a 5% false discovery rate (68). C, MDA-MB-468 cells were treated with DMSO or 1, 3, or 10 M 8a for 30 min. Cells were
harvested, and lysates were subjected to competition MIB/MS as in A. Data were filtered for kinases that showed decreased binding at all three concentrations
in a dose-dependent manner. The 32 kinases that met these criteria are displayed in a heat map, with a double-gradient color scheme ranging from dark blue
(nearly total loss of binding to MIBs) to red (no loss of binding to MIBs). Results are indicative of one experiment.
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pendent decrease in p-H3 (Ser-10), a marker of M that is
induced in G2 and dephosphorylated upon mitotic exit. This
decrease was observed as early as 1 h post-treatment and main-
tained through 24 h.
Histone H3 is phosphorylated at Ser-10 by Aurora B (50). To
be certain that the observed decrease in p-H3 (Ser-10) was not
due to direct inhibition of the Aurora kinases, we utilized the
Thermo Fisher SelectScreen kinase assay to test the effects of 8a
on Aurora A and B activity. Concentrations below 10 M 8a did
not inhibit Aurora A. The IC50 for inhibition of Aurora B was 24
M, and only 10 and 21% inhibition was observed with 1.2 and
3.7 M 8a treatment, respectively. The potency of 8a for the
Aurora kinases was 1000-fold lower than that observed for
MELK (IC50  17 nM) (Fig. S5), indicating that 8a does not
significantly inhibit Aurora A and B. It should also be noted that
these data were from a cell-free enzymatic assay, so inhibition
Figure 3. Treatment with 8a causes decreased viability and decreased phosphorylation of histone H3 (Ser-10) in TNBC cells. A, MDA-MB-231 (left) and
MDA-MB-468 (right) cells were treated with DMSO or 8a at concentrations ranging from 1 nM to 30 M. Cells were exposed to 8a for 72 h before viability was
measured using a resazurin assay. Three biological replicates were completed for each cell line, and representative dose–response curves are displayed here.
B, MDA-MB-231 and MDA-MB-468 cells were treated with DMSO or 8a at the indicated concentrations. The medium was changed, and fresh inhibitor was
added every 2–3 days. Cells were monitored until nearly confluent in the DMSO condition (about 8 or 14 days, respectively), at which point they were stained
with crystal violet and imaged. Three (MDA-MB-231) or two (MDA-MB-468) biological replicates were completed, and representative images are shown here.
C, asynchronous MDA-MB-468 cells were treated with DMSO or 0.5, 1, or 3 M 8a for 1, 6, or 24 h. Cells were harvested and immunoblotted with the indicated
antibodies. Data displayed here are representative of three biological replicates.
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in cells is likely to be considerably weaker at these concentra-
tions. In agreement with this, we did not observe substantial
decreases in Aurora A or B binding to MIBs with 3 M 8a
(Figs. S1 and S3). Collectively, these results show that MELK
inhibition with 8a caused decreased viability through impaired
cell cycle progression, specifically in G2/M phases.
MELK inhibition results in delayed mitotic entry mediated
through delayed activation of Aurora A, Aurora B, and CDK1
Our results prompted further investigation into the effects of
MELK inhibition on cell cycle progression. For subsequent
experiments, HeLaS3 cells were used because of their robust
and well-characterized response to cell cycle synchronization
methods. We first confirmed that HeLaS3 cells exhibit similar
sensitivity to 8a (IC50 of 1.9 M  0.5) as TNBC cell lines (Fig.
S6A). We further observed that 8a treatment caused the same
dose-dependent decrease in p-H3 (Ser-10), with no effect on
PARP cleavage or abundance of the measured cyclins, in
HeLaS3 cells as in MDA-MB-468 cells (Fig. S6B). MELK
expression levels were found to be similar between HeLaS3,
U2OS, and TNBC cell lines as well (Fig. S6C).
To specifically examine effects on progression through G2
and M, HeLaS3 cells were synchronized with double-thymidine
block and released into medium containing DMSO or 1 or 3 M
8a and harvested every 2 h over a 12-h time course. Samples
were immunoblotted for cell cycle markers to determine the
effect of 8a treatment on progression through S phase and into
M (Fig. 4A). No differences in cyclin E1 or A2 abundance were
observed after 8a treatment from 0 to 8 h, indicating that S
phase progression was unaffected by MELK inhibition. At 8 h
after release, p-H3 (Ser-10) abundance was lower in 3 M
8a-treated cells relative to DMSO- and 1 M 8a-treated cells.
Further, at 10 h after release, cyclins A2 and B1 and p-H3 (Ser-
10) abundances were greater with 3 M 8a treatment, indicating
that entry into and progression through M was delayed (Fig.
4B). At the 12-h time point, cells appeared to have completed
M, evident by major decreases in signal for cyclins E1, A2, and
B1 and p-H3 (Ser-10). Cyclin E1 abundance was decreased by 3
M 8a at 12 h, relative to other conditions, suggesting the effects
of mitotic delay may persist after M. Treatment with 1 M 8a
had little effect on cell cycle progression as measured using this
thymidine synchronization technique. Therefore, 3 M 8a was
used in subsequent synchronization experiments.
To further investigate this apparent delay in mitotic entry, we
completed another double-thymidine synchronization experi-
ment with more frequent collections around M (8 –12 h after
release). Cells were not collected between 0 and 6 h after
release, as no differences were observed with 8a over this time
frame in the previous experiment (Fig. 4A). Additionally, we
sought to investigate the mechanism underlying this mitotic
delay further by expanding the number of cell cycle proteins
that were measured by immunoblotting. Aurora A and B have
critical roles in mitotic entry and progression, and their activity
is regulated by autophosphorylation at Thr-288 and Thr-232,
respectively (51, 52). CDK1, regarded as the key kinase for pro-
moting M, is activated by cyclin binding and dephosphorylation
of Tyr-15 and Thr-14. These regulatory sites are phos-
phorylated by Wee1 and Myt1 in interphase, respectively, and
are dephosphorylated by CDC25B (53). We immunoblotted for
Aurora A and B and their regulatory phosphorylation sites,
CDK1 and its regulatory phosphorylation sites, Myt1, Wee1,
CDC25B, and the cell cycle markers used previously (Fig. 5).
With more frequent time points, the delay in onset of M
caused by 3 M 8a was even more apparent than in the previous
experiment. This was evident by delayed degradation of cyclins
A2 and B1, delayed accumulation of the mitotic marker p-H3
(Ser-10), delayed phosphorylation and activation of Aurora A
and B, and delayed activation of CDK1 by dephosphorylation of
Tyr-15 and Thr-14. In control cells, cyclin A2 accumulation
peaked at 7 h after release and persisted through 8.5 h, after
which it was rapidly degraded. In 3 M 8a-treated cells, cyclin
A2 accumulated similarly, but expression persisted through
11 h. Cyclin B1 accumulation was also unaffected by 8a, but its
degradation upon mitotic exit was delayed by 3 h, beginning
at 9 h in control cells and 12 h in 8a-treated cells. Consistent
with this, p-H3 (Ser-10) accumulation began at 8 h and
decreased after 10 h in control cells, compared with accumula-
tion beginning at 9 h, peaking at 11 h, and persisting at high
levels through 12 h in 8a-treated cells. The activation of Aurora
A and B by autophosphorylation was also delayed, correlating
precisely with p-H3 (Ser-10) patterns. CDK1 activation by de-
phosphorylation of Tyr-15 and Thr-14 began at 8.5 h in control
cells, compared with 11 h in 8a-treated cells, whereas CDK1
expression was unaffected. Interestingly, the dynamics of Wee1
expression appeared mostly unchanged between control and 8a
conditions, whereas inactivation of Myt1 by hyperphosphory-
lation (slower migrating band on gel) mirrors the delayed
dephosphorylation pattern observed with CDK1 Thr-14 and
Tyr-15. Finally, the accumulation pattern of CDC25B may also
be unaffected by MELK inhibition, although peak levels of
CDC25B may be decreased relative to control. These results
indicate that MELK inhibition results in delayed mitotic entry
due to a delay in activation of multiple kinases essential for this
process, namely Aurora A and B and CDK1.
MELK inhibition does not impair mitotic completion
After observing that MELK inhibition results in a delay in
mitotic entry, we next asked whether it also had an effect on
mitotic progression and completion. Following the previously
described synchronization/release approach, cells were col-
lected over a 20-h time course and immunoblotted for the same
cell cycle markers (Fig. 6). Again, degradation of cyclins A2 and
B1, and induction of p-H3 (Ser-10) were delayed by 3 M 8a
treatment, correlating with delayed activation of Aurora A and
B and CDK1. Despite this delay, cells treated with 3 M 8a
appeared to progress through and complete M in a similar
amount of time, once M began. This was evident by a return of
p-H3 (Ser-10) to steady-state levels at 14 h, compared with 12 h
for DMSO, and dephosphorylation of Myt1, resulting in a fast-
er-migrating band relative to hyperphosphorylated mitotic
Myt1. MELK expression also decreased rapidly immediately
following completion of M, as described in other studies (4, 35).
HeLaS3 cells treated with 3 M 8a re-entered the subsequent
cell cycle, as observed by an induction of cyclin E1 at 14 h,
compared with 12 h for DMSO. Levels of this G1/S phase cyclin
peak at 16 –18 h with 3 M 8a treatment, which is 2 h later
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than control cells, where cyclin E1 peaks at 14 –16 h. These
results indicate that the length of M appears to be largely unaf-
fected by MELK inhibition, despite mitotic entry being delayed.
These observations, along with delayed activation of Aurora A
and B and CDK1, are consistent with activation of the G2/M
checkpoint (54). Because M occurs quite rapidly (30 min), we
sought to further examine these results using live-cell imaging
for greater temporal resolution.
Live-cell imaging quantifies the mitotic entry delay caused by
MELK inhibition
To more precisely measure the lengths of G2 and M phases in
response to 8a treatment, we conducted live-cell imaging of
U2OS osteosarcoma cells stably expressing a fluorescent cell
cycle reporter based on PCNA localization (55). U2OS cells are
routinely used for cell cycle studies, particularly with imaging
methods, and our results indicate that MELK expression is sim-
ilar between U2OS and TNBC cells (Fig. S6C). This live-cell
imaging approach employs tracking of individual cells from an
unperturbed, asynchronous population. Fluorescent PCNA
delineated the start and end of S phase, whereas nuclear enve-
lope breakdown and cytokinesis delineated the start and end of
M. Cells were treated with DMSO or 1 or 3 M 8a, and G2 length
was measured. We observed significant, dose-dependent G2
lengthening in cells treated with either 1 or 3 M 8a, compared
with DMSO-treated cells (Fig. 7A). In contrast to the lower-
Figure 4. MELK inhibition with 3 M 8a causes delayed mitotic entry. A, HeLaS3 cells were synchronized at G1/S with double-thymidine block and released
into DMSO or 1 or 3 M 8a. Cells were collected every 2 h over a 12-h time course. Cells were lysed and immunoblotted with the indicated antibodies. The splits
in the image indicate that the samples from DMSO and 1 and 3 M 8a conditions were immunoblotted separately due to space constraints. Asynchronous
HeLaS3 lysate was loaded in the lanes labeled A to normalize among the blots. The data shown here are representative of three independent experiments. B,
the signal intensity of the cyclin E1, A2, and B1 and p-H3 (Ser-10) bands was quantified for the replicate shown in A using Bio-Rad Image LabTM software. The
ratio of the quantified signal intensity at each time point relative to the 0-h time point was computed for each condition. The resulting ratios are plotted as bar
charts for each protein, with 1.0 indicating no change relative to the 0-h time point.
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time resolution immunoblotting experiments with synchro-
nized cells (Fig. 4), the increased sensitivity of live-cell imaging
revealed that G2 was indeed significantly lengthened by 1 M 8a
treatment (30% increase, 81 min). Following 3 M 8a treat-
ment, median G2 length was markedly increased (250%
increase, 426 min) compared with untreated cells (Fig. 7C).
Live-cell imaging was next used to quantify the length of M
phase. Whereas no significant difference in time to complete M
was observed between cells treated with DMSO and 1 M 8a, 3
M 8a caused detectable lengthening of M in two of three rep-
licates (Fig. 7B and Fig. S7). This increase in mitotic length from
24 min in control cells to 36 min in 3 M 8a-treated cells was
much smaller in magnitude than the observed increase in G2
(Fig. 7C), which likely explains why it was not detected using
synchronization methods. An increase in G2 length appears to
be the predominant phenotype resulting from MELK inhibi-
tion. Taken together, our results indicate that selective MELK
inhibition causes a delay in mitotic entry that is consistent with
transient G2 arrest.
Discussion
Currently, one of the main questions in the MELK field is
how to rectify the seemingly disparate observations that RNAi-
mediated MELK depletion and pharmacological inhibition
cause a strong growth defect in cancer cells (3–5, 9, 12, 28, 31,
37, 39, 44), whereas CRISPR/Cas9 knockout of MELK may have
conditional or no effect on proliferation (14 –18). It is vital to
recognize that genomic knockout techniques are not identical
to RNAi-mediated knockdown or inhibition, but rather that all
are valuable orthogonal approaches. Thus, divergent results
should be interpreted as evidence that the functional role of the
protein being investigated is likely complex, rather than evi-
dence that one set of results is incorrect in its entirety. It is quite
possible that the total loss of protein expression and activity, via
knockout, could have different effects than partial inhibition
of activity with unperturbed expression, via pharmacological
inhibition. Further, and because of the inherent differences
between these techniques, it is also possible that genomic
knockout could result in cellular reprogramming of signaling
Figure 5. Delayed mitotic entry caused by 8a is associated with delayed activation of Aurora A, Aurora B, and CDK1. HeLaS3 cells were synchronized at
G1/S with double-thymidine block and released into DMSO or 3 M 8a. Cells were collected starting at 6 h after release, with subsequent collections completed
every 0.5 or 1 h, over a 12-h time course. Cells were lysed and immunoblotted with the indicated antibodies. The split in the image indicates that the samples
from DMSO and 3 M 8a conditions were blotted separately due to space constraints. Asynchronous HeLaS3 lysate was loaded in the lanes labeled A to
normalize among the blots. The data shown here are representative of two independent experiments.
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networks such that compensation for growth defects occurs,
whereas partial inhibition or depletion of the same enzyme may
not result in the same changes. As described in the Introduc-
tion, divergent phenotypes have been observed, but not yet fully
explained, between cyclin D-CDK4/6 knockout and inhibition,
demonstrating that this phenomenon is not constrained solely
to MELK (19 –21). At this point, these potential explanations
are purely speculative, but this will undoubtedly be an impor-
tant area of investigation for future MELK studies.
This controversy has underscored the fact that our under-
standing of the function of MELK in cancer is still lacking. As a
further complication, functional studies of MELK have long
relied upon OTS, an inhibitor with a remarkable lack of selec-
tivity, to complement results obtained using knockdown and
other techniques. Whereas RNAi-mediated knockdown and
genomic knockout approaches obviously have their merits, the
use of a pharmacological inhibitor has distinct advantages as
well. First, pharmacological inhibition generally allows for
much tighter temporal control than other techniques, such that
effects can be measured on a short timescale before significant
changes in signaling networks occur. Second, inhibition of
kinase activity often does not directly affect expression of the
inhibited kinase, which allows for differentiation between activ-
ity-dependent and -independent functions. Thus, a selective
MELK inhibitor would clearly be a valuable addition to the tool-
kit available for studying the mechanistic underpinnings of this
kinase in cancer.
In an effort to identify a selective MELK inhibitor, we used
competition MIB/MS technology to evaluate the selectivity
profiles of OTS, HTH, and 8a. Our results (Fig. 2A) are in agree-
ment with other studies in demonstrating that OTS is highly
nonselective and therefore is unsuitable for mechanistic studies
of MELK biology (42, 43). In contrast to published enzyme
assay data demonstrating HTH to be a potent MELK inhibitor,
we found that this inhibitor did not significantly affect MELK
binding to MIBs (Fig. 2, A and B) (15). This illustrates the dis-
parate results that can be observed between enzyme- and cell-
based selectivity-profiling methods, emphasizing the impor-
Figure 6. HeLaS3 cells treated with 8a complete mitosis and begin the subsequent cell cycle following delayed mitotic entry. HeLaS3 cells were
synchronized at G1/S with double-thymidine block and released into DMSO or 3 M 8a. Cells were collected starting at 6 h after release, with subsequent
collections completed every 2 h over a 20-h time course. Cells were lysed and immunoblotted with the indicated antibodies. The split in the image indicates that
the samples from DMSO and 3 M 8a conditions were blotted separately due to space constraints. Asynchronous HeLaS3 lysate was loaded in the lanes labeled
A to normalize among the blots. The data shown here are representative of at least two biological replicates.
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tance of evaluating compound selectivity in a cellular context.
Our results indicating that 8a exhibits high selectivity for
MELK (Fig. 2, A–C) are the first to characterize an exquisitely
selective MELK inhibitor in cells and thus rationalize the use of
8a for future functional studies. Because thoroughly validated
MELK substrates are lacking, one intriguing possibility is to use
MS to compare the phosphoproteome of cells treated with 8a to
control cells, in an effort to identify novel MELK substrates.
Such studies could serve to establish a much-needed cellular
readout for MELK activity and to further elucidate the role of
MELK in the cell cycle and cancer. To date, MELK phospho-
proteomics studies have only been completed using a mutant
null allele of the MELK homolog in Caenorhabditis elegans
(pig-1) (56) or with OTS treatment (13).
As previously described, 8a treatment caused decreased via-
bility of TNBC cells (Fig. 3, A and B) at concentration ranges
that significantly prevented MELK binding to MIBs (Fig. 2C)
(44). We did not observe an induction of apoptosis with 8a (Fig.
3C), despite some others describing this effect as a result of
MELK knockdown (4, 9, 17, 31). It is possible that the longest
time point used in our study (24 h) is not sufficient for induction
of apoptosis with 8a and that the observed cell cycle perturba-
tion precedes apoptosis. Both prosurvival and proapoptotic
roles have been attributed to MELK, and the specific contexts
that determine these opposing functions remain to be eluci-
dated (34).
Although many studies describe a role for MELK in cell cycle
progression, the precise details of this role are not well-under-
stood. In response to MELK silencing with RNAi, numerous
studies have reported an accumulation of cells in G2/M phases
(3, 17, 37, 44, 57). It should be noted that due to the methods
used (quantification of cellular DNA by flow cytometry), these
particular studies were not able to differentiate between an
accumulation in G2 versus M. Paradoxically, overexpression of
MELK may induce a G2/M accumulation of cells as well (3, 38).
Other studies have used more specific techniques to differenti-
ate between G2 and M phase effects. MELK knockdown has
been reported to impair mitotic progression by varied mecha-
nisms, including by decreasing activity and expression of the
oncogenic mitotic transcription factor FoxM1 (28, 39), by reg-
ulating MCL1 synthesis in M (31), by inducing mitotic catas-
trophe (8), and by causing cytokinetic defects (4, 58, 59). A role
for MELK in G2, distinct from M, has been described as well.
Davezac et al. (38) observed that ectopic expression of MELK
(formerly known as pEg3) caused an accumulation of cells in
G2, which could be rescued by co-expression of CDC25B.
MELK was found to directly interact with CDC25B in Xenopus
and phosphorylate this phosphatase in vitro, leading the
authors to hypothesize that MELK negatively regulates the
G2/M checkpoint through interaction with CDC25B (38).
As there is no clear consensus whether MELK plays a role in
G2, M, or both, we used 8a, as an alternative to RNAi knock-
down, to further investigate the cell cycle function of MELK.
Time-lapse microscopy experiments (Fig. 7) indicated that
MELK inhibition caused a major, significant lengthening of G2
phase. Of note, we observed many cells that delayed in G2 phase
after exposure to 8a within that same cell cycle, suggesting that
the G2 delay phenotype is proximal to MELK inhibition. An
additional minor delay in mitotic progression was observed,
warranting further investigation in light of previous studies
indicating that MELK has mitotic functions. However, we
focused on the more predominant delay in mitotic entry. Using
thymidine synchronization techniques (Figs. 4 – 6), we
observed that MELK inhibition caused delayed mitotic entry,
likely mediated through delayed activation of CDK1, which was
ultimately overcome to allow cells to complete M and begin the
subsequent cell cycle. These observations are consistent with a
transient activation of the G2/M checkpoint (54). Further stud-
ies are required to elucidate the underlying mechanism,
Figure 7. 8a causes a major, dose-dependent increase in G2 length. A,
asynchronous U2OS cells harboring fluorescent PCNA were treated with
DMSO or 1 or 3 M 8a. Microscopy images were acquired every 6 min over the
course of 72 h. Cells were manually tracked, and the length of G2 was calcu-
lated by measuring the amount of time between disappearance of PCNA foci
(end of S phase) and nuclear envelope breakdown (start of M). For each of
three biological replicates, 50 cells were tracked per condition. Kaplan–Meier
curves were generated, and significance was calculated in GraphPad Prism
using the log-rank test for survival curves. Representative data are shown
here, and results from additional replicates are shown in Fig. S7. B, the length
of M was manually calculated in the cells in A by measuring the amount of
time between nuclear envelope breakdown (start of mitosis) and cytokinesis
(end of mitosis). For each of three biological replicates, 50 cells were tracked
per condition. Curves were generated, and significance was calculated as in A.
Data shown here, indicating M to be significantly lengthened by 3 M 8a, are
representative of two of three biological replicates. Additional experiments
(Fig. S7) indicate that M was not significantly lengthened in one replicate. C,
median length of G2 and M, in minutes. The displayed cell cycle phase lengths
were calculated for the experiment shown in A and B.
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although it is possible to speculate based upon the work of
others.
One potential explanation for the observed G2 delay pheno-
type is that MELK positively regulates CDC25B in G2, such that
inhibition of MELK causes CDC25B to be unable to dephos-
phorylate and activate CDK1, thereby delaying mitotic entry.
MELK phosphorylates multiple sites on CDC25B to regulate
both progression through the G2/M checkpoint and CDC25B
localization to centrosomes during M (38, 60). Importantly, this
putative interaction has never been examined in the context of
cancer. A possible interaction with CDC25C, which has a crit-
ical role at the G2/M checkpoint and shares high sequence ho-
mology with CDC25B, has not been explored either. Additional
studies are needed to more clearly define the interaction
between MELK and the CDC25 phosphatases in cancer. An
alternative hypothesis is that MELK inhibition causes DNA
damage, which subsequently activates the G2/M checkpoint. A
study by Beke et al. (39) found that MELK inhibition with
MELK-T1 caused replication stress in MCF-7 cells, manifesting
in replication fork stalling and DNA double-strand breaks. This
resulted in activation of the ATM/Chk2 DNA damage repair
pathway, which stimulates the G2/M checkpoint (39, 61).
Although this pathway would certainly explain the putative
checkpoint activation, one would also expect strong ATM acti-
vation to lengthen S phase, which was not observed in our study
(Fig. 4).
In conclusion, we have validated 8a as a highly selective
MELK inhibitor suitable for functional studies and have shown
that MELK inhibition causes a mitotic delay consistent with
activation of the G2/M checkpoint.
Experimental procedures
Antibodies and reagents
MELK-8a hydrochloride was purchased from MedChemEx-
press (HY-100368A). OTSSP167 was purchased from Selleck
Chemicals (S7159). HTH-01-091 was a generous gift from Dr.
Nathanael Gray (Harvard University). The following primary
antibodies were used in this study. Aurora A (14475, 1:1000),
Aurora B (3094, 1:1000), CDC25B (9525, 1:1000), cyclin A2
(4656, 1:2000), cyclin E1 (4129, 1:2500), MELK (2274, 1:1000),
Myt1 (4282, 1:1000), PARP (9532, 1:1000), phospho-Aurora
A/B/C (2914, 1:1000), phospho-CDK1 (Thr-14) (2543, 1:1000),
phospho-CDK1 (Tyr-15) (4539, 1:1000), and p-H3 (Ser-10)
(9701, 1:1000) were purchased from Cell Signaling Technology.
-Actin (SC47778, 1:500) was purchased from Santa Cruz Bio-
technology, Inc. CDK1 (MAB8878, 1:2000) was purchased
from Millipore. Cyclin B1 (ab32053, 1:10,000) was purchased
from Abcam.
Cell culture and viability assays
MDA-MB-468 and MDA-MB-231 cells were kindly pro-
vided by Dr. Gary Johnson (University of North Carolina).
These cell lines were cultured in RPMI 1640 (Gibco) supple-
mented with 10% fetal bovine serum (FBS; Millipore) and 1%
antibiotic-antimycotic (Sigma). HeLaS3 cells were kindly pro-
vided by Dr. Michael Emanuele (University of North Carolina)
and were cultured in Dulbecco’s modified Eagle’s medium
(DMEM), high-glucose (Gibco), supplemented with 10% FBS
and 1% antibiotic-antimycotic.
Resazurin assays were completed as described previously
(62). Briefly, MDA-MB-231 (1500 cells/well), MDA-MB-468
(4000 cells/well), or HeLaS3 (1000 cells/well) cells were plated
on a 96-well plate. After 24 h, medium was aspirated and
replaced with fresh medium containing 8a at concentrations
ranging from 1 nM to 30 M or DMSO (negative control). Each
treatment condition was tested in technical quadruplicate.
Cells were incubated in medium with 8a or DMSO for 72 h
prior to the addition of resazurin dye (0.6 mM, Acros Organics
62758-13-8). After color change was observed (3 h for MDA-
MB-231, 2 h for MDA-MB-468, 0.75 h for HeLaS3), signaling
that measurable reduction of resazurin to resorufin had
occurred, fluorescence intensity was measured using a
PHERAstar (BMG Labtech) plate reader with fluorescence
module (FI: 540-20, 590-20). Dose-response curves were cre-
ated, and IC50 values were calculated using GraphPad Prism
version 8.
For crystal violet assays, MDA-MB-231 and MDA-MB-468
cells were seeded at a density of 5000 and 10,000 cells/well,
respectively, on each well of a cell culture-treated 6-well plate
(Corning, Inc.). The following day, medium was aspirated from
all wells and replaced with medium supplemented with either
DMSO or 0.1, 0.3, 1, 3, or 10 M 8a. Every 2 days throughout the
course of the assay, medium was replaced on all wells with fresh
medium containing 8a or DMSO. Cells were observed daily
using a bright-field microscope, and confluence was noted. The
assay was continued until cells in the DMSO well were observed
to be nearly confluent (8 days for MDA-MB-231 and 14
days for MDA-MB-468). Medium was then aspirated from all
wells, and cells were washed gently with ice-cold PBS (Gibco).
Next, 2 ml of crystal violet stain (0.5% crystal violet (w/v)
(Sigma), 20% methanol (Fisher)) was gently added to each well,
and plates incubated for 10 min at room temperature. Wells
were subsequently washed three times with water and allowed
to dry, and plates were imaged with a Canon LiDE 110 docu-
ment scanner.
Double-thymidine synchronization
HeLaS3 cells were seeded on 6-cm plates and allowed to
adhere overnight. During this and all subsequent incubation
steps, cells were maintained in a humidified chamber with 5%
CO2 at 37 °C. DMEM was aspirated from all plates (except for
asynchronous control plates, which were maintained in an
incubator until the end of the assay) and replaced with medium
supplemented with 2 mM thymidine (Sigma). 16 h after thymi-
dine block, medium was aspirated, plates were washed with
warm PBS (1) and warm DMEM (2), and fresh medium was
added for release from block. Plates were incubated for 9 h, at
which point medium was aspirated and again replaced with
DMEM supplemented with 2 mM thymidine and incubated for
16 h. Medium was aspirated and cells were washed as above and
released from thymidine block into DMEM supplemented with
8a or DMSO. 0-h time points were collected at the time of
release, and subsequent collections were completed at the time
points shown in the figures. Cells were collected by scraping in
medium, and cell suspension was transferred to a 15-ml conical
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tube. Cells were pelleted at 3000 rcf in a centrifuge with swing-
ing bucket rotor, washed with cold PBS, and stored at 80 °C.
After all time points were collected, cell pellets were lysed and
prepared for immunoblotting as described below.
Immunoblotting
HeLaS3 cells were plated in 6-well plates and treated with
DMSO or 0.5, 1, or 3 M 8a for 1, 2, 4, 8, 12, or 24 h. Cells were
collected as described above for double-thymidine synchroni-
zation protocol. Pellets from asynchronous and synchronized
experiments were lysed by the addition of radioimmune precip-
itation assay buffer (20 mM Tris, pH 7.4, 137 mM NaCl, 10%
glycerol, 0.5% sodium deoxycholate, 1% Nonidet P-40 substi-
tute (Fluka), 0.1% SDS, 2 mM EDTA) supplemented with pro-
tease and phosphatase inhibitors (2 mM Na(VO3)4, 10 mM NaF,
0.0125 M calyculin A, and cOmplete EDTA-free protease
inhibitor mixture (Roche Applied Science). Benzonase was
added to each lysate (42 units/sample), and samples were incu-
bated on ice for 10 min. Lysates were clarified by centrifugation
at 21,000 rcf, 4 °C for 15 min. Protein concentrations were nor-
malized by Bradford assay (Bio-Rad) and prepared for SDS-
PAGE by the addition of 4 Laemmli sample buffer (250 mM
Tris, pH 6.8, 40% glycerol, 8% SDS, 8% -mercaptoethanol,
0.4% bromphenol blue). Samples (10 –30 g) were applied to a
10% SDS-polyacrylamide gel for separation of proteins, after
which proteins were transferred to a polyvinylidene difluoride
membrane (Bio-Rad). Membranes were blocked for 1 h with 5%
nonfat dry milk or 5% BSA (for phosphospecific antibodies) in
TBS-T (20 mM Tris, pH 7.6, 137 mM NaCl, 0.05% Tween 20).
Membranes were incubated in primary antibody dilutions
(described above) in 5% BSA made in TBS-T at 4 °C with gentle
shaking. Following overnight incubation, membranes were
washed with TBS-T three times and incubated for 1 h at room
temperature with anti-mouse or -rabbit IgG-HRP– conjugated
secondary antibody (Promega) dilutions in 5% milk in TBS-T.
Membranes were again washed three times in TBS-T, and
bands were imaged using a Chemi-Doc Touch Imaging System
(Bio-Rad) after the addition of Clarity ECL reagent (Bio-Rad).
MIB/MS selectivity-profiling sample preparation
The selectivity of MELK inhibitors for kinase targets was pro-
filed using competition MIB/MS. MDA-MB-468 cells were
treated with MELK inhibitor, at concentrations listed in the
figure legends, or DMSO for 30 min. This time point is suffi-
cient for kinase engagement and inhibition by compound, but
insufficient for major expression-level changes. Cells were then
washed twice with ice-cold PBS before being scrape-harvested
in PBS. Cell lysis, sample preparation, and MIB kinase enrich-
ment were completed as described previously (63), with the
exception of the composition of the kinase inhibitor mix used
for enrichment. To enrich for kinases in each sample, a 350-l
volume of the following kinase inhibitors, immobilized on
beads, was applied to one Poly-Prep chromatography column
(Bio-Rad) per sample: CTx-0294885, PP58, Purvalanol B,
UNC2147A, VI-16832, and UNC8088A.
LC-MS/MS analysis
Samples were analyzed by LC-MS/MS using a Thermo Easy
nLC 1200 coupled to an Orbitrap Q Exactive HF mass spec-
trometer equipped with an EasySpray nano source. Samples
were loaded onto an EasySpray C18 column (75-m inner
diameter  25 cm, 2-m particle size) and eluted over a 120-
min method. The gradient for separation consisted of 5– 40% B
at a 250-nl/min flow rate, where mobile phase A was water,
0.1% formic acid, and mobile phase B was 80% acetonitrile, 0.1%
formic acid. The Q Exactive HF was operated in data-depen-
dent mode, where the 15 most intense precursors were selected
for subsequent fragmentation. Resolution for the precursor
scan (m/z 350 –1700) was set to 120,000 with a target value of
3  106 ions, 100-ms maximum injection time. MS/MS scans
resolution was set to 15,000 with a target value of 1  105 ions,
75-ms maximum injection time. The normalized collision
energy was set to 27% for higher-energy collisional dissociation.
Dynamic exclusion was set to 30 s, and precursors with
unknown charge or a charge state of 1 and 8 were excluded.
MS data analysis
Data were processed using the MaxQuant software suite
(version 1.6.1.0) (64, 65). The data were searched against a
reviewed Uniprot human database (downloaded in February
2018) containing 20,245 sequences. Precursor mass tolerance
was set to 4.5 ppm, and fragment mass tolerance was set to 20
ppm. A maximum of two missed tryptic cleavages were allowed.
The fixed modification specified was carbamidomethylation of
cysteine residues. The variable modification specified was oxi-
dation of methionine. A default protein false discovery rate
(FDR) of 1% was used to filter all data within MaxQuant. Pro-
teins were quantified across all samples using MaxLFQ (66).
Matching between runs was allowed with the default retention
time window. Kinases were parsed from the data set, and those
with 1 unique peptide were quantified using label-free quan-
tification (LFQ). Kinases with 50% missing values were
removed, and LFQ intensities for the missing values were
imputed using a constant value (average lower 10% of all LFQ
intensities). The ratio of the LFQ intensity for each kinase in
MELK inhibitor conditions to that kinase in DMSO control was
computed. GraphPad Prism version 8 was used to generate bar
plots and heat maps. For data used to generate volcano plots,
kinases that were not quantified in all three replicates in at least
one condition within each analysis were removed. Missing LFQ
values were then imputed by randomly sampling from a normal
distribution with a mean of 1.8 S.D. values lower than the mean
in the original data, and an S.D. value of 0.3 times the S.D. in the
original data. Data were log2-transformed, and moderated t
tests were computed using the Limma package (67). Briefly, a
linear model predicting signal intensity given treatment condi-
tion was fit for each kinase, followed by t statistics calculated by
empirical Bayes moderation of S.E. values toward the S.E. esti-
mated from all kinases. Multiple-test correction was performed
using the Benjamini–Hochberg method to control for a 5% FDR
(68). The MS proteomics data have been deposited to the Pro-
teomeXchange Consortium via the PRIDE (69) partner repos-
itory with the data set identifier PXD016022.
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U2OS cells were a gift from Dr. Michael Whitfield (Dart-
mouth College) and maintained in DMEM (Sigma) supple-
mented with 10% FBS (Sigma), 1 penicillin-streptomycin, and
4 mM L-glutamine and incubated at 5% CO2. Cells were trans-
duced with fluorescent PCNA (pLenti-Hyg-turq2-PCNA) and
histone H2B (pBabe-Puro-mCh-H2B) using standard tech-
niques, as described previously (55). One day prior to imaging,
cells were plated on #1.5 glass-bottom plates (Cellvis) in Fluo-
roBrite DMEM (Gibco) supplemented with FBS, penicillin-
streptomycin, and L-glutamine, as above. Imaging was per-
formed on a Nikon Ti Eclipse inverted microscope using a 40
(numerical aperture 0.95) Plan Apochromat dry objective lens
and the Nikon Perfect Focus System. Still images were captured
using an Andor Zyla 4.2 sCMOS detector with 12-bit resolu-
tion. During imaging, cells were maintained in a humidified
chamber with 5% CO2 at 37 °C. Filter sets were as follows: CFP,
436/20 nm; 455 nm; 480/40 nm (excitation; beam splitter; emis-
sion filter) and mCherry, 560/40 nm; 585 nm; 630/75 nm
(Chroma). Images were obtained every 6 min using NIS-Ele-
ments AR software. No photobleaching or phototoxicity was
observed in cells imaged with this protocol.
8a or DMSO (negative control) was added 24 h after the
beginning of the imaging run as described in the figure legends.
Cells were manually tracked and scored. The onset and end of S
phase were determined visually using the DNA replication–
associated patterns of PCNA localization in the nucleus. Mito-
sis length was defined visually by the length of time between
nuclear envelope breakdown and cytokinesis. Three individual
biological replicates were imaged with 50 cells counted per con-
dition per replicate. Cells that traveled out of the field of view or
did not complete a cell cycle (S phase to cytokinesis) were
excluded from the analysis.
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